Skip to main content
. Author manuscript; available in PMC: 2017 Mar 20.
Published in final edited form as: Eur J Immunol. 2017 Jan 25;47(3):458–469. doi: 10.1002/eji.201646855

Figure 6.

Figure 6

Aqp4ΔT × Rag1−/− mice immunized with AQP4(201–220) peptide plus i.v. application of rAb-53 develop inner nuclear layer (INL) swelling at disease onset. Aqp4ΔT × Rag1−/− mice were immunized with either AQP4(201–220) or MOG(35–55) peptide emulsified in CFA. After immunization, the mice were injected i.v. with rAb-53 antibody or IC-05 control antibody on day 12 after immunization. Retinal optical coherence tomography (OCT) was performed in the indicated treatment groups prior to immunization (baseline) and on day 13 after immunization at the onset of disease (and 1 day after administration of control antibody IC-05 or anti-AQP4 antibody rAb-53). Mean INL volumes of individual eyes ± SD are shown. *p < 0.05, ns = not significant (Student’s t-test). One experiment with six mice per group is shown.